标题
Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
作者
关键词
-
出版物
EUROPEAN HEART JOURNAL
Volume 43, Issue 31, Pages 2931-2945
出版商
Oxford University Press (OUP)
发表日期
2022-06-18
DOI
10.1093/eurheartj/ehac299
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study
- (2022) Peter Rossing et al. DIABETES CARE
- Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial
- (2022) Gerasimos Filippatos et al. EUROPEAN JOURNAL OF HEART FAILURE
- Generalizability of FIGARO‐DKD and FIDELIO‐DKD Trial Criteria to the US Population Eligible for Finerenone
- (2022) Nicholas Chiu et al. Journal of the American Heart Association
- Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms
- (2022) Johann Bauersachs et al. Kidney International Supplements
- Antagonistic effects of finerenone and spironolactone on the aldosterone‐regulated transcriptome of human kidney cells
- (2021) Florian Le Billan et al. FASEB JOURNAL
- Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats
- (2021) Asadur Rahman et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study
- (2021) George Bakris et al. HYPERTENSION
- Finerenone Reduces Onset of Atrial Fibrillation in Patients with Chronic Kidney Disease and Type 2 Diabetes
- (2021) Gerasimos Filippatos et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
- (2021) Peter Kolkhof et al. AMERICAN JOURNAL OF NEPHROLOGY
- Finerenone: First Approval
- (2021) James E. Frampton DRUGS
- Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
- (2021) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change
- (2021) Sudeep R. Aryal et al. Journal of the American Heart Association
- The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
- (2021) Frédéric Jaisser et al. Frontiers in Pharmacology
- Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
- (2021) Gerasimos Filippatos et al. CIRCULATION
- Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
- (2021) Peter Rossing et al. DIABETES OBESITY & METABOLISM
- Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
- (2021) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
- (2021) Javed Butler et al. EUROPEAN JOURNAL OF HEART FAILURE
- Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial
- (2021) Rajiv Agarwal et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders − New perspectives for combination therapy
- (2021) Peter Kolkhof et al. PHARMACOLOGICAL RESEARCH
- Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy
- (2021) Peter Rossing et al. Kidney International Reports
- Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial
- (2020) Pierpaolo Pellicori et al. EUROPEAN JOURNAL OF HEART FAILURE
- Structural determinants of activation of the mineralocorticoid receptor: an evolutionary perspective
- (2020) Peter J. Fuller et al. JOURNAL OF HUMAN HYPERTENSION
- Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study
- (2020) Takashi Wada et al. Clinical and Experimental Nephrology
- Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
- (2020) Rajiv Agarwal et al. EUROPEAN HEART JOURNAL
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN)
- (2020) Sadayoshi Ito et al. Clinical Journal of the American Society of Nephrology
- Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice
- (2019) Abdus Sattar Bhuiyan et al. HYPERTENSION RESEARCH
- The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone
- (2019) Krister Bamberg et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Esaxerenone: First Global Approval
- (2019) Sean Duggan DRUGS
- Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association
- (2019) Janani Rangaswami et al. CIRCULATION
- Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: Rationale and design of the ALDOCURE trial
- (2019) Joachim Alexandre et al. AMERICAN HEART JOURNAL
- Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial
- (2019) Heerajnarain Bulluck et al. AMERICAN HEART JOURNAL
- A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients
- (2019) Fabian Hammer et al. KIDNEY INTERNATIONAL
- Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study
- (2019) Andrew Whittaker et al. CTS-Clinical and Translational Science
- Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
- (2019) Sadayoshi Ito et al. HYPERTENSION
- Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator
- (2018) Fredrik Erlandsson et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction
- (2018) Marianne Lachaux et al. DIABETES OBESITY & METABOLISM
- Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone’s Antifibrotic ActivityNovelty and Significance
- (2018) Jana Grune et al. HYPERTENSION
- Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion
- (2018) Krister Bamberg et al. PLoS One
- Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies
- (2018) Bryan Williams et al. Lancet Diabetes & Endocrinology
- Cardiorenal Syndrome Revisited
- (2018) Faiez Zannad et al. CIRCULATION
- Macrophage Mineralocorticoid Receptor Is a Pleiotropic Modulator of Myocardial Infarct Healing
- (2018) Daniela Fraccarollo et al. HYPERTENSION
- Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial
- (2018) David M. Charytan et al. KIDNEY INTERNATIONAL
- Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
- (2018) Raquel González-Blázquez et al. Frontiers in Pharmacology
- Canrenone on cardiovascular mortality in congestive heart failure
- (2018) Giuseppe Derosa et al. PHARMACOLOGICAL RESEARCH
- Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF
- (2017) João Pedro Ferreira et al. EUROPEAN JOURNAL OF HEART FAILURE
- Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease
- (2017) Evan B. Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
- (2017) Peter Kolkhof et al. JOURNAL OF ENDOCRINOLOGY
- Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?
- (2016) Hermann Haller et al. CURRENT HYPERTENSION REPORTS
- Mineralocorticoid receptor antagonists—pharmacodynamics and pharmacokinetic differences
- (2016) Jun Yang et al. CURRENT OPINION IN PHARMACOLOGY
- Cardiac Tissue Injury and Remodeling Is Dependent Upon MR Regulation of Activation Pathways in Cardiac Tissue Macrophages
- (2016) Jimmy Z. Shen et al. ENDOCRINOLOGY
- Finerenone in heart failure: walking a fine line
- (2016) Matthias Naegele et al. EUROPEAN HEART JOURNAL
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
- (2016) Gerasimos Filippatos et al. EUROPEAN HEART JOURNAL
- Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis
- (2016) RenJie Lu et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy
- (2016) Jana Grune et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Mineralocorticoid regulation of cell function: the role of rapid signalling and gene transcription pathways
- (2016) Gregory S Y Ong et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Early Aldosterone Blockade in Acute Myocardial Infarction
- (2016) Farzin Beygui et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Adult nephron-specific MR-deficient mice develop a severe renal PHA-1 phenotype
- (2016) Jérémie Canonica et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease
- (2015) Peter Bramlage et al. EUROPEAN JOURNAL OF HEART FAILURE
- Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
- (2015) Kiyoshi Arai et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Cardiomyocyte Mineralocorticoid Receptor Activation Impairs Acute Cardiac Functional Recovery After Ischemic InsultNovelty and Significance
- (2015) Laura A. Bienvenu et al. HYPERTENSION
- Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy
- (2015) George L. Bakris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
- (2015) Larbi Amazit et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Direct and Indirect Mineralocorticoid Effects Determine Distal Salt Transport
- (2015) A. S. Terker et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial
- (2015) Bryan Williams et al. LANCET
- Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study
- (2014) G. Montalescot et al. EUROPEAN HEART JOURNAL
- Identification and characterization of a ligand-selective mineralocorticoid receptor coactivator
- (2014) Fraser M. Rogerson et al. FASEB JOURNAL
- Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
- (2014) Peter Kolkhof et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy
- (2014) A Gupta et al. JOURNAL OF HUMAN HYPERTENSION
- Myeloid Mineralocorticoid Receptor Activation Contributes to Progressive Kidney Disease
- (2014) L. L. Huang et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Spironolactone for Heart Failure with Preserved Ejection Fraction
- (2014) Bertram Pitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
- (2013) Bertram Pitt et al. EUROPEAN HEART JOURNAL
- Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis
- (2013) Nancy J. Brown Nature Reviews Nephrology
- PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
- (2013) Stephen Orena et al. Frontiers in Pharmacology
- Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
- (2012) Lars Bärfacker et al. ChemMedChem
- The Ubiquitous Mineralocorticoid Receptor: Clinical Implications
- (2012) Urseline A. Hawkins et al. CURRENT HYPERTENSION REPORTS
- Cardiomyocyte Mineralocorticoid Receptors Are Essential for Deoxycorticosterone/Salt-Mediated Inflammation and Cardiac Fibrosis
- (2012) Amanda J. Rickard et al. HYPERTENSION
- Deletion of Cardiomyocyte Mineralocorticoid Receptor Ameliorates Adverse Remodeling After Myocardial Infarction
- (2011) Daniela Fraccarollo et al. CIRCULATION
- Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction
- (2011) S. Kasama et al. HEART
- Mechanisms of ligand specificity of the mineralocorticoid receptor
- (2011) Peter J Fuller et al. JOURNAL OF ENDOCRINOLOGY
- Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
- (2011) Peter Kolkhof et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice
- (2010) Michael G. Usher et al. JOURNAL OF CLINICAL INVESTIGATION
- Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
- (2010) Faiez Zannad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myeloid-Specific Deletion of the Mineralocorticoid Receptor Reduces Infarct Volume and Alters Inflammation During Cerebral Ischemia
- (2010) Ryan A. Frieler et al. STROKE
- Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results
- (2009) Alessandro Boccanelli et al. EUROPEAN JOURNAL OF HEART FAILURE
- Deletion of Mineralocorticoid Receptors From Macrophages Protects Against Deoxycorticosterone/Salt-Induced Cardiac Fibrosis and Increased Blood Pressure
- (2009) Amanda J. Rickard et al. HYPERTENSION
- Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease
- (2009) Nicola C. Edwards et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A Comparison of the Aldosterone-blocking Agents Eplerenone and Spironolactone
- (2008) Allan Struthers et al. CLINICAL CARDIOLOGY
- Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone
- (2008) P. Mulder et al. EUROPEAN HEART JOURNAL
- Cardiorenal Syndrome
- (2008) Claudio Ronco et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist
- (2007) Frances McManus et al. Nature clinical practice. Endocrinology & metabolism
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now